ReviewFuture microbiology2011
Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
Review in Future microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 68 citations in OpenAlex.
- Evaluation of long-term consequences among snakebite survivors in rural Kenya including validation of a functional limitations assessment tool.PLoS neglected tropical diseases · 2026Article
- Buruli ulcer.Nature reviews. Disease primers · 2025Review
- TheeLife · 2025Article
- Buruli ulcer: An epidemiological update from Japan.The Journal of dermatology · 2025Review
- Mycolactone causes destructive Sec61-dependent loss of the endothelial glycocalyx and vessel basement membrane: a new indirect mechanism driving tissue necrosis inbioRxiv : the preprint server for biology · 2024Article
- Memory B-cells are enriched in the blood of patients with acute Buruli ulcer disease: a prospective observational study.BMC infectious diseases · 2023Observational
- Protective Efficacy of BCG Vaccine againstVaccines · 2022Review
- Drug Efficacy Testing in the Mouse Footpad Model of Buruli Ulcer.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Analysis of key genes inFrontiers in tropical diseases · 2022Article
- Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer.Antimicrobial agents and chemotherapy · 2021Article
- The Many Hosts of Mycobacteria 8 (MHM8): A conference report.Tuberculosis (Edinburgh, Scotland) · 2020Review
- Buruli ulcer treatment: Rate of surgical intervention differs highly between treatment centers in West Africa.PLoS neglected tropical diseases · 2019Article
- Mycolactone Toxin Membrane Permeation: Atomistic versus Coarse-Grained MARTINI Simulations.Biophysical journal · 2019Article
- Recombinant Antibodies against Mycolactone.Toxins · 2019Article
- Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer.Antimicrobial agents and chemotherapy · 2019Article
- Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.PLoS neglected tropical diseases · 2018Article
- Report of a series of 82 cases of Buruli ulcer from Nigeria treated in Benin, from 2006 to 2016.PLoS neglected tropical diseases · 2018Article
- In Silico Prediction of Antibiotic Resistance inThe American journal of tropical medicine and hygiene · 2017Article
- The chemistry and biology of mycolactones.Beilstein journal of organic chemistry · 2017Review
- Combatting AMR: photoactivatable ruthenium(ii)-isoniazid complex exhibits rapid selective antimycobacterial activity.Chemical science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Until 2004, the skin disease known as Buruli ulcer, caused by Mycobacterium ulcerans, could only be treated by surgery and skin grafting. Although this worked reasonably well on early lesions typically found in patients in Australia, the strategy was usually impractical on large lesions resulting from diagnostic delay in patients in rural West Africa. Based on promising preclinical studies, treatment trials in West Africa have shown that a combination of rifampin and streptomycin administered daily for 8 weeks can kill M. ulcerans bacilli, arrest the disease, and promote healing without relapse or reduce the extent of surgical excision. Improved treatment options are the focus of research that has increased tremendously since the WHO began its Global Buruli Ulcer Initiative in 1998.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.